Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of MK-0616 for prevention of major adverse cardiovascular events in high-risk adults
MOH_2023-09-12_012922Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerosis and hypercholesterolemia comparing MK-0616 plus statin therapy with Placebo plus statin therapy (2 arms). Started Aug 2023; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
atherosclerosishypercholesterolemia
Beyond the preview
Go deeper on MOH_2023-09-12_012922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-12_012922.